Diffuse intrinsic pontine glioma (DIPG) is one of the deadliest central nervous system tumors of childhood, with a median overall survival of less than 12 months. Convection-enhanced delivery has been proposed as a means to efficiently deliver therapeutic agents directly into the brainstem while minimizing systemic exposure and associated toxic effects. We did this study to evaluate the safety of convection-enhanced delivery of a radioimmunotherapy agent targeting the glioma-associated B7-H3 antigen in children with diffuse intrinsic pontine glioma.
TLC has been supporting the efforts of Dr. Mark Souweidane since 2018 to expand on his existing Phase 1 trial, which has been referred to as groundbreaking by the Lancet Oncology. The peer-reviewed publication in the Lancet validates a career-long hypothesis that Dr. Souweidane put forth more than 20 years ago, and was only made possible by the families who entrusted their children in his care by enrolling in the trial, and the donors who have provided the financial support to enable this research (read his inspiring blog here).
The results are so promising, they are expected to eventually change the landscape of future pediatric brain tumor protocols.
View the most recent related article accrediting the TLC Foundation here.
PHOTO CREDIT: HUMANS OF NEW YORK, BRANDON STANTON
